NZ305626A - Reversible protease inhibitors - Google Patents

Reversible protease inhibitors

Info

Publication number
NZ305626A
NZ305626A NZ305626A NZ30562696A NZ305626A NZ 305626 A NZ305626 A NZ 305626A NZ 305626 A NZ305626 A NZ 305626A NZ 30562696 A NZ30562696 A NZ 30562696A NZ 305626 A NZ305626 A NZ 305626A
Authority
NZ
New Zealand
Prior art keywords
protease inhibitors
compounds
optionally substituted
reversible protease
2nhr14
Prior art date
Application number
NZ305626A
Inventor
James T Palmer
David Rasnick
Original Assignee
Axys Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharm Inc filed Critical Axys Pharm Inc
Publication of NZ305626A publication Critical patent/NZ305626A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

rovided are compounds as depicted and their salts in which n is 0 to 13; A-B represents a linkage selected from -CONR3-, -CH2NR3- and -NR3CO-; Y is -CH(R5)- or -N(R5)-; Z is -(CH2)2-, -C(R6)(R7)- or -N(R7)-; Z1 is -(CH2)2-, -C(R6)(R8)- or -N(R8)-; R1 is H, alkoxycarbonylalkanoyl, carbonylalkoxy, an optionally substituted alkanoyl,cycloalkylcarbonyl, an optionally substituted heterocycloalkylcarbonyl, arylalkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylaminosulfonyl or heteroarylsulfonyl; X represents a bond, -CH2-, or -CH2CH(R4)-, wherein R4 is hydrogen, alkyl or arylalkyl; R9 is cyano, -COOR10, P(O)(OR10)2, -S(O)(NR10)R10, -C(O)R11, -S(O)R11, -CONR12R13, -S(O)2NR12R13, -CONHR14 OR -S(O)2NHR14; and the remaining symbols are defined in the specification. These compounds are reported to be cysteine protease inhibitors
NZ305626A 1995-03-24 1996-03-21 Reversible protease inhibitors NZ305626A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40999695A 1995-03-24 1995-03-24
PCT/US1996/003844 WO1996030353A1 (en) 1995-03-24 1996-03-21 Reversible protease inhibitors

Publications (1)

Publication Number Publication Date
NZ305626A true NZ305626A (en) 2000-01-28

Family

ID=23622800

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ305626A NZ305626A (en) 1995-03-24 1996-03-21 Reversible protease inhibitors

Country Status (15)

Country Link
EP (1) EP0817778A1 (en)
JP (1) JPH11503417A (en)
KR (1) KR19980703261A (en)
CN (1) CN1071751C (en)
AU (1) AU713492B2 (en)
CA (1) CA2216151A1 (en)
CZ (1) CZ298197A3 (en)
IL (1) IL117638A0 (en)
MY (1) MY113489A (en)
NO (1) NO311573B1 (en)
NZ (1) NZ305626A (en)
PL (1) PL322409A1 (en)
TW (1) TW470750B (en)
WO (1) WO1996030353A1 (en)
ZA (1) ZA962336B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332390A (en) 1996-04-22 2000-07-28 Brigham & Womens Hospital Suppression of immune response via inhibition of Cathepsin S by vinyl sulfone derivatives
NZ333713A (en) * 1996-07-30 2000-12-22 Axys Pharm Inc Compounds for treating diseases associated with tryptase activity
DE19817461A1 (en) 1998-04-20 1999-10-21 Basf Ag New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
EP1159273A1 (en) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
NZ518255A (en) * 1999-09-13 2004-11-26 Boehringer Ingelheim Pharma Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
ATE364689T1 (en) 1999-11-18 2007-07-15 Dendreon Corp NUCLEIC ACIDS WHICH CODE FOR ENDOTHELIASES, ENDOTHELIASES, AND THEIR USE
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6635633B2 (en) 2000-08-14 2003-10-21 Ortho-Pharmaceutical, Inc. Substituted pyrazoles
RU2317988C2 (en) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Substituted pyrazoles, pharmaceutical composition based on thereof, using pharmaceutical composition and method for inhibition of cathepsin s activity
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
AU2001281255B2 (en) 2000-08-14 2006-07-20 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
WO2002020002A2 (en) 2000-09-06 2002-03-14 Ortho Mcneil Pharmaceutical, Inc. A method for treating allergies
WO2002048097A1 (en) * 2000-12-12 2002-06-20 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
JP2004523506A (en) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド Novel compounds and compositions as cathepsin inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
WO2003024923A1 (en) * 2001-09-14 2003-03-27 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
MXPA04002282A (en) * 2001-09-14 2005-03-07 Axis Pharmaceutical Inc Novel compounds and compositions as cathepsin inhibitors.
RU2004117877A (en) 2001-11-14 2006-01-10 Авентис Фармасьютикалз Инк. (Us) OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM, AS CATATEPSIN S INHIBITORS
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
JP2011524340A (en) * 2008-05-21 2011-09-01 ニュー・ワールド・ラボラトリーズ・インコーポレイテッド Selective caspase inhibitors and uses thereof
WO2010133000A1 (en) 2009-05-21 2010-11-25 New World Laboratories Inc. Selective caspase inhibitors and uses thereof
WO2011069149A2 (en) 2009-12-04 2011-06-09 Dcb-Usa Llc Cathepsin s inhibitors
US9944674B2 (en) 2011-04-15 2018-04-17 Genesis Technologies Limited Selective cysteine protease inhibitors and uses thereof
KR101309578B1 (en) * 2011-05-06 2013-09-17 연세대학교 산학협력단 Dityrosine compounds having selectivity for cysteine proteases and method for monitoring cysteine proteases using the same
KR101385855B1 (en) * 2012-10-16 2014-04-22 이동익 Diaromatic amino acid-based substrate for detecting cathepsins
WO2019142890A1 (en) * 2018-01-19 2019-07-25 株式会社大阪ソーダ Organosilicon compound and rubber composition including same
EP3553521A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits

Also Published As

Publication number Publication date
CZ298197A3 (en) 1998-03-18
AU713492B2 (en) 1999-12-02
CN1071751C (en) 2001-09-26
CN1184472A (en) 1998-06-10
MY113489A (en) 2002-03-30
IL117638A0 (en) 1996-07-23
WO1996030353A1 (en) 1996-10-03
ZA962336B (en) 1996-07-31
JPH11503417A (en) 1999-03-26
EP0817778A1 (en) 1998-01-14
TW470750B (en) 2002-01-01
NO974403D0 (en) 1997-09-23
PL322409A1 (en) 1998-01-19
KR19980703261A (en) 1998-10-15
AU5367496A (en) 1996-10-16
NO974403L (en) 1997-11-17
NO311573B1 (en) 2001-12-10
CA2216151A1 (en) 1996-10-03

Similar Documents

Publication Publication Date Title
NZ305626A (en) Reversible protease inhibitors
IT1130252B (en) METHOD FOR THE ELIMINATION OF BILIRIBUNA INTERFERENCE IN THE DOSAGE OF HYDROGEN PEROXIDE THROUGH A MODIFIED TRINDER REACTION
MX9700584A (en) Pesticide.
ATE40884T1 (en) INTERMEDIATE COMPOUNDS FOR THE PRODUCTION OF OMEPRAZOLE.
ES2054951T3 (en) 3-ARIL-PIRROLIDIN-2,4-DIONAS.
PL318557A1 (en) Ligands of retinic acid x-receptors
DE69516053D1 (en) Generation of a diamond film
ES8302025A1 (en) 10-Alkynyl steroids
NO983963D0 (en) Mono- and dider derivatives of cyclodextrins, synthesis thereof and purification and use thereof as a carrier
FI852806A0 (en) 2-SUBSTITUERADE -1,3-PROPYLIDENDIPHOSPHONATDERIVAT OCH DERAS FRAMSTAELLNING.
CO5011087A1 (en) VITRONECTINE RECEPTORS ANTAGONISTS
CO5090837A1 (en) DERIVATIVES OF 1,3,4-OXADIAZOLONA
MY121565A (en) Fluorine-containing compounds and use thereof
ITMI912765A0 (en) PROCEDURE FOR ISOMERIZING 1,1,2-TRIFLUORO-1,2-DICHLOROETHEHANE TO 1,1,1- TRIFLUORO-2,2,-DICHLOROETHHANE
GR3003575T3 (en)
AU3451295A (en) Bicycloaliphatic 2-methylene-1,3-dioxepanes
TW328945B (en) Carbamoylcarboxamides
AU545216B2 (en) 2-(4-benzylpiperidino)-1-(4 halo-phenyl)piopan-1-ol
NO20003138L (en) New application of local anesthetics to vascular headaches
DE3880499T2 (en) CYANHYDRINE DERIVATIVES AND THEIR USE IN LIQUID CRYSTAL MATERIALS AND DEVICES.
JPS646245A (en) Benzylamine derivative, production thereof and germicide containing said derivative as active ingredient
AU2845489A (en) Process for preparing hydroxyakylating agents, the agents so obtained, and their use
TW368517B (en) Liquid crystal alkene-cyclohexene derivatives, liquid crystal composite and liquid crystal display component
ATE31063T1 (en) 2,6-DIOXABICYCLO-(2,2,2>-OCTAN-7-YLACETALDEHYDE.
EP0237438A3 (en) Process for the preparation of polyene aldehydes

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)